Highlights•COVID-19 patients have increased incidence of Epstein-Barr Virus reactivation.•Detection of EBV DNA is greater among COVID-19 positive patients (27.1% vs 12.5%).•No statistical difference in CRP levels of COVID-19 positive vs. negative patients.•No statistical difference in amount of EBV genomes in reactivated patient groups.